| Primary | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score at Week 24 in Intent-to-treat (ITT) Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | ITT population. Number of participants analysed=participants with available data for this endpoint. Here, 'n' signifies participants with available data at specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| | | Title | Denominators | Categories |
|---|
| Baseline (n=142) | | | | Change From Baseline at Week 24 (n=118) | | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Analysis was performed using paired sample t-test for change from baseline. | Paired sample T-test | | <0.0001 | | | | | | 2-Sided | | | | | | | No | Superiority or Other | | |
|
| Secondary | Change From Baseline in Bone Mineral Density (BMD) in Lumbar Spine, Total Hip and Femoral Neck Regions at End of Study | BMD was measured by dual energy X-ray absorptiometry (DXA) and T-scores (a standard deviation [SD] compared with the peak BMD value of an adult aged from 20 to 30 years) were calculated. Osteopenia was defined by a T-score between -1 and -2.5 SD and osteoporosis as a T-score below -2.5 SD, according to the World Health Organization (WHO) guidelines. T-scores for L1-L4 lumbar spine, total spine, total hip (left), and femoral neck (left) were calculated. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number of participants with available data for specified category. | Posted | | Mean | Standard Deviation | T-score | | Baseline, End of the study (up to Week 100) | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Number of Participants Achieving Remission According to Disease Activity Score 28 (DAS28) at Weeks 24, 48, 72, and 96 | Remission was defined as DAS28 score less than (<) 2.6. The DAS28 score was a measure of the participant's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity (visual analog scale [VAS]: 0=no disease activity to 100=maximum disease activity) and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. In case of missing ESR value, C-Reactive Protein (CRP) was used to calculate DAS28. Higher scores represented higher disease activity. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Number | | participants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Percentage of Participants Achieving Remission According to DAS28 at Weeks 24, 48, 72, and 96 | Remission was defined as DAS28 score <2.6. The DAS28 score was a measure of the participant's disease activity calculated using the TJC [28 joints], SJC [28 joints], patient's global assessment of disease activity (VAS: 0=no disease activity to 100=maximum disease activity) and the ESR for a total possible score of 0 to approximately 10. In case of missing ESR value, CRP was used to calculate DAS28. Higher scores represented higher disease activity. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies number of participants with available data for specified category. | Posted | | Number | | percentage of participants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Percentage of Participants With DAS28 Good or Moderate European League Against Rheumatism (EULAR) Response at Weeks 24, 48, 72 and 96 | The DAS28 score was a measure of the participant's disease activity calculated using the TJC [28 joints], SJC [28 joints], patient's global assessment of disease activity (VAS: 0=no disease activity to 100=maximum disease activity) and the ESR for a total possible score of 0 to approximately 10. In case of missing ESR value, CRP was used to calculate DAS28. Higher scores represented higher disease activity. EULAR Good response: DAS28 ≤3.2 and a change from Baseline <-1.2. EULAR Moderate response: DAS28 greater than (>) 3.2 to less than or equal to (≤) 5.1 or a change from Baseline <-0.6 to greater than or equal to (≥) -1.2. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies number of participants with available data for specified category. | Posted | | Number | | percentage of participants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Percentage of Participants Achieving Remission and Low Disease Activity According to Simplified Disease Activity Index (SDAI) at Weeks 24, 48, 72, and 96 | SDAI was calculated by a simple numerical sum of tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity (VAS 0-10 centimeter [cm]), and level of CRP. SDAI total score 0-86; higher scores = greater effect due to disease activity. Remission was defined as SDAI score ≤3.3. Low disease activity was defined as SDAI score ≤11.0. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies number of participants with available data for specified category. | Posted | | Number | | percentage of participants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Percentage of Participants Achieving Remission and Low Disease Activity According to Clinical Disease Activity Index (CDAI) at Weeks 24, 48, 72, and 96 | CDAI was calculated by a simple numerical sum of tender and swollen joint count (based on 28-joint assessment) and the patient and physician global disease assessment (VAS 0-10 cm). CDAI total score 0-76; higher scores = greater effect due to disease activity. Remission was defined as CDAI score ≤2.8. Low disease activity was defined as CDAI score ≤10.0. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies number of participants with available data for specified category. | Posted | | Number | | percentage of participants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Change From Baseline in TJC At Weeks 24, 48, 72, and 96 | 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from baseline indicated improvement. | ITT population. Here, 'n' signifies the number of participants with available data at specified timepoints. | Posted | | Mean | Standard Deviation | tender joints | | Baseline; Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 48 in ITT Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | ITT population. Number of participants analyzed=participants with available data at specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 72 in ITT Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | ITT population. Number of participants analyzed=participants with available data at specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 96 in ITT Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | ITT population. Number of participants analyzed=participants with available data at specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 24 in Per Protocol (PP) Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | Per Protocol (PP) population: all participants who completed the study. Number of participants analyzed=participants with available data for this outcome. Here 'n' signifies the participants with available data for specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 48 in PP Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | Per Protocol (PP) population. Number of participants analyzed=participants with available data for specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 48 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 72 in PP Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | Per Protocol (PP) population. Number of participants analyzed=participants with available data for specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 72 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Primary | Change From Baseline in FACIT Fatigue Score at Week 96 in PP Population | The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worst score) to 52 (best score). | Per Protocol (PP) population. Number of participants analyzed=participants with available data for specified time point. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline, Week 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Change From Baseline in SJC At Weeks 24, 48, 72, and 96 | 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from baseline indicated improvement. | ITT population. Here, 'n' signifies the number of participants with available data at specified timepoints. | Posted | | Mean | Standard Deviation | swollen joints | | Baseline; Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR50 and ACR70 Response at Weeks 24, 48, 72, and 96 | ACR20 response: ≥20% improvement in TJC; ≥20% improvement in SJC; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; Patient Global Assessment of Disease Activity (PtGA); Physician Global Assessment of Disease Activity (PGA); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ-DI]); and either CRP or ESR. ACR50 response required ≥50% improvement in the above criteria and ACR70 response required ≥70% improvement in the above criteria. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Number | | percentage of partcipants | | Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Change From Baseline in Hemoglobin at Weeks 20, 44, 72 and 96 | | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Mean | Standard Deviation | gram per deciliter | | Baseline; Weeks 20, 44, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| | |
| Secondary | C-reactive Protein Level | | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Mean | Standard Deviation | milligram per deciliter | | Baseline; Weeks 8, 16, 24, 36 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| | |
| Secondary | Erythrocyte Sedimentation Rate | | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Mean | Standard Deviation | millimeter per hour | | Baseline; Weeks 8, 16, 24, 36 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| | |
| Secondary | Participant Assessment of Pain (VAS) | The mean score of pain as assessed by participants using a 100-mm horizontal VAS, where the left endpoint (0) indicated "No pain," and the right endpoint (100) indicated "Unbearable pain". Higher score indicated higher pain. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Mean | Standard Deviation | mm | | Baseline; Weeks 8, 16, 24, 36 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |
| Secondary | Change From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 72, and 96 | HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. | ITT population. Number of participants analyzed=participants with available data for this endpoint. Here, 'n' signifies the number participants with available data for specified category. | Posted | | Mean | Standard Deviation | units on a scale | | Baseline; Weeks 24, 48, 72 and 96 | | | | ID | Title | Description |
|---|
| OG000 | Tocilizumab | Participants received tocilizumab 8 mg/kg IV infusion every 4 weeks for a period of 96 weeks. |
| |